MLYS | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 20%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.92%

1 Month

-4.53%

3 Months

-21.14%

6 Months

-23.49%

1 Year

98.81%

2 Year

114.40%

Key data

Stock price

$28.43

P/E Ratio

0.00

DAY RANGE

$24.37 - $31.00

EPS

-$3.44

52 WEEK RANGE

$10.44 - $47.65

52 WEEK CHANGE

$116.86

MARKET CAP

2.514 B

YIELD

N/A

SHARES OUTSTANDING

79.140 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.91

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,410,447

AVERAGE 30 VOLUME

$1,186,962

Company detail

CEO: Jon Congleton
Region: US
Website: mineralystx.com
Employees: 0
IPO year: 2023

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. We were originally founded as a Delaware corporation on May 31, 2019 under the name Catalys SC1, Inc. On May 29, 2020, we changed our name to Mineralys Therapeutics, Inc. Our principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA.

MLYS - Mineralys Therapeutics, Inc.